Drug Profile
Research programme: macrocyclic compounds - Cyclenium Pharma/Haplogen
Alternative Names: Anti-viral therapeutics - Cyclenium Pharma/HaplogenLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Cyclenium Pharma; Haplogen
- Class Antivirals; Macrocyclic compounds; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Viral-infections in USA (PO)
- 06 Jun 2023 Cyclenium Pharma has been acquired by SpiroChem
- 03 Jan 2022 Early research development is ongoing in Viral infections in USA (PO) (Cyclenium Pharma pipeline, January 2022)